Novartis AG announced that it has received a favorable opinion for Pluvicto a radioligand therapy, in combination with androgen deprivation therapy (ADT) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). Furthermore, the positive opinion is based on data from the Phase III VISION study, which would significantly improve overall survival in PSMA-positive mCRPC patients and provide transformative innovation to more patients around the world.
Sun Pharmaceutical Industries Ltd. teamed up with Philogen SpA for the commercialization of Nidlegy, a brand-new immunotherapy drug that Philogen is creating to treat both melanoma and non-melanoma skin cancers in New Zealand, Australia, and Europe.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5047
Published Date: Oct 20, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising prevalence of Cushing syndrome and the growing launch of advanced drug therapies for rare diseases are the major factors driving the growth of the market.
The market size of somatostatin analogs is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.
The major players in the market are Novartis AG, Sun Pharmaceutical Industries Ltd, Midatech Pharma PLC, Ipsen Pharma, Chiasma Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc, and Pfizer Inc.
The octreotide segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.